Physician profile
Forest Hawk Mealey
NPI 1780664136
$3,012.28
in general payments reported to CMS, 2019-2025
18 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $57.42 · 2024: $2,209 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,730 · Food and Beverage: $690 · Education: $123 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,730.22 |
| Food and Beverage | $689.65 |
| Education | $122.61 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,149.84 | 2024 | |
| Olympus Corporation of The Americas | $956.46 | 2024 | Spiration Valve System |
| Actelion Pharmaceuticals US, INC. | $210.83 | 2019-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $143.96 | 2019-2020 | |
| United Therapeutics Corporation | $133.62 | 2019-2025 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $88.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $57.53 | 2019 | |
| Insmed, INC. | $54.82 | 2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $50.83 | 2024-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Resmed Corp | $35.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.98 | 2019 | |
| Portola Pharmaceuticals, LLC | $25.41 | 2019 | |
| Circassia INC. | $18.15 | 2019 | |
| Pfizer INC. | $17.05 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.49 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forest Mealey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.